A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.

@article{Chou2012A2P,
  title={A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.},
  author={Hubert S. Chou and Kenneth E. Truitt and James B. Moberly and Domenico Merante and Y I Choi and Yong Mun and A Pf{\"u}tzner},
  journal={Diabetes, obesity & metabolism},
  year={2012},
  volume={14 11},
  pages={1000-9}
}
AIMS To evaluate the efficacy and safety of rivoglitazone, a peroxisome proliferator-activated receptor γ agonist in the thiazolidinedione class, in subjects with suboptimally controlled type 2 diabetes mellitus (T2DM). METHODS Subjects aged ≥18 years with T2DM and haemoglobin A1c (HbA1c) >7.0% and ≤8.5%, who were treatment naïve or receiving a non… CONTINUE READING